TW202128692A - 吡啶并嘧啶類衍生物的結晶形式及其製備方法 - Google Patents

吡啶并嘧啶類衍生物的結晶形式及其製備方法 Download PDF

Info

Publication number
TW202128692A
TW202128692A TW109147161A TW109147161A TW202128692A TW 202128692 A TW202128692 A TW 202128692A TW 109147161 A TW109147161 A TW 109147161A TW 109147161 A TW109147161 A TW 109147161A TW 202128692 A TW202128692 A TW 202128692A
Authority
TW
Taiwan
Prior art keywords
crystal form
formula
compound represented
compound
solvent
Prior art date
Application number
TW109147161A
Other languages
English (en)
Chinese (zh)
Inventor
吳琪
杜振興
王捷
王林
陸偉棟
邵啟雲
馮君
峰 賀
Original Assignee
大陸商江蘇恒瑞醫藥股份有限公司
大陸商上海恒瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恒瑞醫藥股份有限公司, 大陸商上海恒瑞醫藥有限公司 filed Critical 大陸商江蘇恒瑞醫藥股份有限公司
Publication of TW202128692A publication Critical patent/TW202128692A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW109147161A 2020-01-02 2020-12-31 吡啶并嘧啶類衍生物的結晶形式及其製備方法 TW202128692A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010002822.9 2020-01-02
CN202010002822 2020-01-02

Publications (1)

Publication Number Publication Date
TW202128692A true TW202128692A (zh) 2021-08-01

Family

ID=76686512

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109147161A TW202128692A (zh) 2020-01-02 2020-12-31 吡啶并嘧啶類衍生物的結晶形式及其製備方法

Country Status (10)

Country Link
US (1) US20230058425A1 (fr)
EP (1) EP4085914A4 (fr)
JP (1) JP2023509175A (fr)
KR (1) KR20220123437A (fr)
CN (1) CN114929232B (fr)
AU (1) AU2020416484A1 (fr)
CA (1) CA3163386A1 (fr)
MX (1) MX2022008286A (fr)
TW (1) TW202128692A (fr)
WO (1) WO2021136488A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022184113A1 (fr) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 Composition pharmaceutique comprenant un dérivé de pyridopyrimidine et son procédé de préparation
WO2024125636A1 (fr) * 2022-12-16 2024-06-20 上海拓界生物医药科技有限公司 Polythérapie avec un modulateur de récepteur de type toll et un arn double brin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03002577A (es) 2000-09-26 2003-06-30 Unilever Nv Composicion que comprende una fase grasa, materia vegetal y sal.
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
MY150481A (en) 2008-03-03 2014-01-30 Irm Llc Compounds and compositions as tlr activity modulators
ES2732999T3 (es) 2009-08-07 2019-11-27 Glaxosmithkline Biologicals Sa Derivados de oxoadenina lipidada
WO2011068233A1 (fr) 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines agissant par l'intermédiaire des récepteurs de type toll (tlr)
EP2563366A4 (fr) 2010-04-30 2013-11-20 Univ California Utilisations de conjugués phospholipidiques d'agonistes synthétiques de tlr7
WO2012058671A1 (fr) * 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Dérivés de quinazoline et de pyrido-pyrimidine substituées
WO2012066336A1 (fr) 2010-11-19 2012-05-24 Astrazeneca Ab Composés de benzylamine à titre d'agonistes du récepteur toll-like 7
US9034336B2 (en) 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
TW201410657A (zh) 2012-08-02 2014-03-16 Endo Pharmaceuticals Inc 經取代胺基－嘧啶衍生物
SI3097102T1 (en) * 2015-03-04 2018-02-28 Gilead Sciences, Inc. A TOOL RECEPTOR MODULING 4,6-DIAMINO-PYRIDO (3,2-D) PYRIMIDINE COMPOUNDS
CA2997955A1 (fr) * 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulateurs de recepteurs de type toll pour le traitement du vih
CN108055842B (zh) 2015-09-17 2021-06-29 豪夫迈·罗氏有限公司 亚磺酰基苯基或磺亚胺酰基苯基苯并氮杂䓬
ES2826748T3 (es) * 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
TW201945003A (zh) * 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN110526918B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法
AU2019299609B9 (en) 2018-07-03 2024-07-11 Jiangsu Hengrui Medicine Co., Ltd. Pyridopyrimidine derivative, preparation method therefor and medical use thereof

Also Published As

Publication number Publication date
WO2021136488A1 (fr) 2021-07-08
CN114929232B (zh) 2023-06-16
EP4085914A1 (fr) 2022-11-09
KR20220123437A (ko) 2022-09-06
AU2020416484A1 (en) 2022-08-25
MX2022008286A (es) 2022-08-08
EP4085914A4 (fr) 2023-06-21
CN114929232A (zh) 2022-08-19
US20230058425A1 (en) 2023-02-23
JP2023509175A (ja) 2023-03-07
CA3163386A1 (fr) 2021-07-08

Similar Documents

Publication Publication Date Title
WO2021136488A1 (fr) Forme cristalline d'un dérivé de pyridopyrimidine et son procédé de préparation
TWI705060B (zh) 一種ｍｅｋ激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法
JP7472138B2 (ja) Ｓｙｋ阻害剤の塩及びその結晶形
CN110526918B (zh) 一种吡唑并杂芳基类衍生物的晶型及制备方法
WO2023093861A1 (fr) Mono-p-toluènesulfonate d'inhibiteur de kinase axl et forme cristalline de celui-ci
CN113461661B (zh) 6-(吡啶-3-基)喹唑啉-4(3h)-酮类衍生物及其制备和应用
CA3083019A1 (fr) Derive de pyrimidine sulfamide, son procede de preparation et son utilisation medicale
CN110194741B (zh) 4-苯甲酰哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其制备方法和应用
WO2019056003A1 (fr) Co-cristaux de neflamapimod (vx -745)
CA3216045A1 (fr) Composes utilises en tant qu'inhibiteurs de pd1/pd-l1 et procedes associes
TWI704916B (zh) 一種吡唑并雜芳基類衍生物鹽酸鹽的晶型及製備方法
TWI824626B (zh) Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
CN110272388B (zh) 4-二硫代甲酸哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其合成方法和应用
WO2024109871A1 (fr) Sel pharmaceutiquement acceptable d'un composé hétérocyclique contenant de l'azote, forme cristalline de celui-ci et procédé de préparation associé
WO2023078411A1 (fr) Composé azaspiro
CN111217748B (zh) 一种螺环二氢异喹啉甲酰胺类衍生物的晶型及其制备方法
CN110283123B (zh) 4-对甲苯磺酰基哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其合成方法和应用
WO2024165035A1 (fr) Forme cristalline d'un dérivé de sulfonamide et son procédé de préparation
WO2022247942A1 (fr) Sel pharmaceutiquement acceptable et forme cristalline de dérivé cyclique de pyridine fusionné et son procédé de préparation
TWI788444B (zh) Ｆｇｆｒ４抑制劑晶型及其製備方法
WO2021185312A1 (fr) Forme cristalline d'un agoniste de tlr8
CN112225732B (zh) 一种盐酸哌罗匹隆水合物晶型及其制备方法
TW202421624A (zh) 用作泛素－特異性蛋白酶抑制劑的羰基稠合雜環衍生物
CN110526917A (zh) 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
CN117263879A (zh) 二甲基吗啉衍生物的制备方法